Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

Codiak BioSciences (Nasdaq: CDAK) announced that President and CEO Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021, from 12:10-12:30 p.m. ET. The event will focus on Codiak's pioneering work in exosome-based therapeutics, aimed at treating diseases with high unmet medical needs. A webcast can be accessed via the Codiak website, with archived replays available for 30 days.

CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E. Williams, Ph.D., President and CEO, will participate in a virtual fireside chat at the 4^th Annual Evercore ISI HealthCONx Conference. Details are as follows:

4^th Annual Evercore ISI HealthCONx Conference
Date: December 2, 2021
Time: 12:10-12:30 p.m. ET

A webcast of the virtual presentation will be available on the Investors & Media section of the Codiak website at https://ir.codiakbio.com/. Archived replays will be available for approximately 30 days following the event.

About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of diseases, spanning oncology, neuro-oncology, infectious disease and rare disease. 

Investor Contact:
Christopher Taylor
VP, Investor Relations and Corporate Communications
T: 617-949-4220
E: investor@codiakbio.com

Media Contact:
Lindy Devereux
Scient PR
T: 646-515-5730
E: lindy@scientpr.com

FAQ

What is the purpose of Codiak BioSciences' participation in the conference?

Codiak BioSciences will discuss its advancements in exosome-based therapeutics at the 4th Annual Evercore ISI HealthCONx Conference.

When is the 4th Annual Evercore ISI HealthCONx Conference?

The conference will be held on December 2, 2021, from 12:10-12:30 p.m. ET.

Where can I watch the Codiak BioSciences presentation?

The presentation can be viewed on the Investors & Media section of the Codiak website.

How long will the Codiak BioSciences conference webcast be available?

The archived replay of the conference will be available for approximately 30 days.

What is the focus of Codiak BioSciences' research?

Codiak focuses on developing exosome-based therapeutics for treating a variety of diseases, including oncology and rare diseases.